Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect



CAS Number: 81846-19-7

Therapeutic Category
API Technology
Dose Form
Oral Solid/Tablets
Injectable Solution
Dr Reddy's Development Status
Innovator Brand (USA)
Orenitram, Remodulin, Tyvaso

Mechanism of Action

Treprostinil is a stable analogue of prostacyclin5,6,7, a prostaglandin that acts as an anti-thrombotic agent and a potent vasodilator. Prostacyclin analogues are useful in the treatment of pulmonary arterial hypertension (PAH), a disease characterized by abnormally high blood pressure in the arteries between the heart and lungs.3 PAH leads to right heart failure due to the remodelling of pulmonary arteries, and patients with this condition have a poor prognosis.4

Treprostinil binds and activates the prostacyclin receptor, the prostaglandin D2 receptor 1, and the prostaglandin E2 receptor 2.3 The activation of these receptors leads to the elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, which consequently promotes the opening of calcium-activated potassium channels that lead to cell hyperpolarization.3 This mechanism promotes the direct vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation1,5,6,7. In addition to its direct vasodilatory effects, treprostinil inhibits inflammatory pathways.


The FDA has indicated treprostinil for the treatment of pulmonary arterial hypertension5,6,7 and pulmonary hypertension associated with interstitial lung disease5 to improve exercise ability. It is also used to treat pulmonary arterial hypertension in patients requiring transition from epoprostenol.6 The Health Canada label specifies that treprostinil is indicated for the long-term treatment of pulmonary arterial hypertension in NYHA Class III and IV patients who did not respond adequately to conventional therapy

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Trepostinil API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Trepostinil API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Cardiovascular API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.